Efficacy of 9-Valent HPV Vaccine in Young Women
This was the first phase 3 efficacy clinical trial of a 9-valent HPV vaccine.
Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143-2159.